bioRxivCancer BiologyPreprint
Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics
J. L. Rose, S. Srinivasan, W. Yao, S. Seth, M. Peoples, A. Machado, C.-Y. Li, I. L. Ho, J. J. Lee, P. A. Guerrero, E. Kim, M. Syed, J. R. Daniele, A. Deem, M. Kim, C. A. Bristow, E. J. Koay, G. Genovese, A. Viale, T. P. Heffernan, A. Maitra, T. Hart, A. Carugo, G. F. Draetta
Abstract
Cancers are highly complex ecosystems composed of molecularly distinct sub-populations of tumor cells, each exhibiting a unique spectrum of genetic features and phenotypes, and embedded within a complex organ context. To substantially improve clinical outcomes, there is a need to comprehensively define inter- and intra-tumor phenotypic diversity, as well as to understand the genetic dependencies that underlie discrete molecular subpopulations. To this end, we integrated CRISPR-based co-dependency annotations with a tissue-specific co-expression network developed from patient-derived models to establish CoDEX, a framework to quantitatively associate gene-cluster patterns with genetic vulnerabilities in pancreatic ductal adenocarcinoma (PDAC). Using CoDEX, we defined multiple prominent anticorrelated gene-cluster signatures and specific pathway dependencies, both across genetically distinct PDAC models and intratumorally at the single-cell level. Of these, one differential signature recapitulated the characteristics of classical and basal-like PDAC molecular subtypes on a continuous scale. Anchoring genetic dependencies identified through functional genomics within the gene-cluster signature defined fundamental vulnerabilities associated with transcriptomic signatures of PDAC subtypes. Subtype-associated dependencies were validated by feature-barcoded CRISPR knockout of prioritized basal-like-associated genetic vulnerabilities (SMAD4, ILK, and ZEB1) followed by scRNAseq in multiple PDAC models. Silencing of these genes resulted in a significant and directional clonal shift toward the classical-like signature of more indolent tumors. These results validate CoDEX as a novel, quantitative approach to identify specific genetic dependencies within defined molecular contexts that may guide clinical positioning of targeted therapeutics.
- organism: human
- assay: scRNA-seq
- research focus: gene regulatory network inference
- research focus: clustering
- research focus: differential expression
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Limits of Molecular Signatures for Pancreatic Ductal Adenocarcinoma Subtyping
Manuela Lautizi, Jan Baumbach, … Tim Kacprowski·NAR CancerPeer-reviewed·Sep 28, 2022
- Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing
He Dong, Frederick S. Vizeacoumar, … Franco J. Vizeacoumar·bioRxiv·Dec 3, 2025
- Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses
Archana Bhardwaj, Claire Josse, … Kristel Van Steen·Scientific ReportsPeer-reviewed·Jun 30, 2022
- Coexisting morpho-biotypes unveil the regulatory bases of phenotypic plasticity in pancreatic ductal adenocarcinoma
P. Di Chiaro, L. Nacci, … G. Natoli·Cancer CellPeer-reviewed·Apr 1, 2024
- Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach
M. Hilmi, F. Delecourt, … J. Cros·bioRxiv·Nov 16, 2023
- ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
P. Moreno, Y. Ohara, … S. P. Hussain·bioRxiv·Mar 12, 2024